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The new antiviral agent, azidothymidine (AZT; BW A509U), is currently the only successful drug in use for
patients with acquired immunodeficiency syndrome. The effect of this thymidine analog, 3'-azido-3'-
deoxythymidine, on the replication of the lymphadenopathy-associated virus strain of the human immunode-
ficiency virus was evaluated by using susceptible H9 and Jurkat cells. Cells were pretreated with concentrations
of drug ranging from 0.5 to 100 ,uM, infected, and maintained in medium containing drug. Virus production
was assayed by reverse transcriptase assays, and virus-specific DNA was analyzed by Southern blots probed
with cloned human immunodeficiency virus sequences. At 4 to 8 days postinfection, infected cells without drug
reached a peak of reverse transcriptase activity that was sustained. Increasing concentrations of AZT caused
increasing delays in virus production; however, replicate cultures at nontoxic levels of the drug (up to 25 ,uM)
eventually produced as much virus as did non-drug-treated infected cells, despite the continued presence of the
drug. Levels of intracellular, unintegrated, virus-specific DNA paralleled reverse transcriptase levels.
Virus-caused cytopathic effect was likewise delayed in drug-treated cultures. Virus recovered from H9 cultures
after 25 ,uM AZT treatment did not appear resistant to AZT.
Current therapies for acquired immunodeficiency syn-
drome (AIDS) (17, 18) have been directed at the step in the
virus life cycle which, to date, is most readily blocked: the
transcription of the human immunodeficiency virus (HIV)
RNA into its DNA copy by the viral enzyme reverse
transcriptase (RT), encoded by the viral pol gene. Attempts
to interrupt the virus life cycle are made more complicated
by the fact that the virus may remain latent in some cells for
long periods, with later reactivation and production of virus
by incompletely understood mechanisms (5). It is thought
that continued virus infection of newly formed CD4+ T cells
is responsible for the progressive loss of immune function.
Thus, ideally, treatment would prevent virus production in
diseased patients. Cell-to-cell spread of virus is also possible
by fusion of infected cells with susceptible uninfected cells
(4).
The thymidine analog azidothymidine (AZT), or 3'-azido-
3'-deoxythymidine (BW A509U), blocks expression of the
core gag protein (p24) in H9 cells after the cells are exposed
to HIV (10). The drug itself cannot inhibit (RT) in vitro; the
drug is phosphorylated in the cell to the triphosphate form by
host cell enzymes, and this form binds to the HIV RT (6).
The drug is capable of inhibiting the replication of HIV in
MT4 cells infected with human T-cell lymphotropic virus
type I, but has no effect on an already infected HIV-
producing cell line (11). In mice infected with Rauscher
murine leukemia virus, there were significant survival gains
even when the drug was started late in the course of disease
(13).
In a phase 1 clinical trial, a majority of patients with AIDS
showed increases in numbers of circulating helper T cells
(CD4+) during therapy, yet virus continued to be recovered
despite therapy (19). In a phase 2 efficacy trial of AZT in
patients with late AIDS-related complex and AIDS, the drug
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reduced both opportunistic infections and death. Some pa-
tients have had to reduce the dosage of AZT or discontinue
AZT treatment because of drug toxicity leading to, mainly,
anemia or neutropenia (D. Barry and S. N. Lehrman, Abstr.
UCLA Symp. Mol. Cell. Biol. 1987, P019, p. 37). It is
important to know if patients who fail while on AZT therapy
are developing resistant strains of HIV or if the original virus
present in the patient is being produced despite drug treat-
ment.
We have examined the ability of AZT to interfere with
HIV replication in T cells in culture, confirming that AZT
could suppress infection of susceptible cells in culture.
However, we have also found, in contrast to previous
reports, that concentrations of AZT as high as 25 ,uM were
unable to continue preventing the synthesis of virus-specific
DNA and subsequent virus production despite constant drug
exposure. In preliminary tests, the virus produced in the
presence of drug did not develop obvious resistance to AZT.
MATERIALS AND METHODS
Cells and virus strains. H9 cells were kindly provided by
Robert Gallo, and Jurkat cells were provided by Kent
Weinhold. Both T-cell lines were grown in RPMI 1640 with
10% fetal calf serum. Viability determinations were per-
formed by trypan blue exclusion. The BLAV strain of HIV
was obtained from Luc Montagnier, and working stocks
were produced in H9 cells. The pBenn2 plasmid, containing
a portion of the lymphadenopathy-associated virus (LAV)
strain genome, was obtained from Malcolm Martin.
Virus infections. H9 cells (8 x 106) or Jurkat cells (4 x 106)
were pretreated for 4 h in the appropriate concentration of
drug, pelleted, suspended in 1 ml of medium, and then mixed
with 1 ml of a mixture of virus and DEAE-dextran (final
concentration, 2 ,ug/ml) plus or minus drug. After 1 to 2 h at
37°C, cells were washed twice in medium containing the
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FIG. 1. Toxicity ofAZT for uninfected H9 and Jurkat cells. Cells
(5 x 104/ml) in triplicate cultures were adjusted to the drug concen-
trations given. Averages of log of total cells per milliliter from
triplicate cultures are plotted versus time in the drug. Drug concen-
trations: no drug (V), 0.5 mM (+), 5 FM (O), 25 ,uM (A), and 100
,uM (x).
appropriate level of AZT and seeded at 2.5 x 105 to 4 x
105/ml in medium containing drug. Every time cells were
counted, percentage of viability was determined, and cells
were pelleted from their medium and replaced at a density of
2 x 1051m1 into new medium containing drug. Clarified
supernatant fluids were stored at -70°C until experiments
were completed, and RT levels were determined in all
samples in parallel.
RT assay. A variation of the procedure of Poiesz et al. (12)
was used to detect the presence of virus-associated RT.
Clarified supernatant medium (6.5 ml) was adjusted to final
concentrations of 0.1 M NaCl and 9% polyethylene glycol
8000 and kept on ice overnight. Virus was pelleted at 11,950
x g in a Sorvall SS-34 rotor at 4°C for 10 min. The pellet was
suspended in 0.1 M NaCI-0.05 M Tris (pH 7.5) to give a 13 x
or 26x concentration of the original supernatant fluid. Con-
centrated virus (30 1.l) was added to duplicate reactions
containing 5 ,uCi of [3H]TTP (60 to 80 Ci/mmol; Amersham
Corp.), final concentrations of 10 mM Tris (pH 7.5), 8 mM
MgCl2, 10 mM dithiothreitol, 0.5% Triton X-100, 50 pLg of
poly(A) per ml, and 10 ,ug of oligo(dT)12_18 (Pharmacia, Inc.)
per ml. After incubation of the reaction mixtures at 37°C for
1 h, 40 ,ul of each duplicate reaction was spotted onto DE81
filter paper (Whatman, Inc.) and washed six times in 5%
Na2HPO4 followed by two washes each of water and etha-
nol. The dried filters were counted in Betafluor scintillation
fluid.
DNA analyses. Cell culture volumes were increased 2 days
preceding a harvest of DNA; low-molecular-weight DNA
was isolated from cells by the method of Hirt (8). DNA
samples were subjected to electrophoresis through 0.8%
agarose gels and blotted onto nitrocellulose (Schleicher &
Schuell, Inc.) by the method of Southern (14). Filters were
hybridized to [32P]dCTP-labeled, nick-translated probes
made from the LAV 6.44-kilobase HindIlI fragment
subcloned into the Bluescribe M13 vector (Vector Cloning
Systems). Prehybridization and hybridization solutions were
in 50% formamide as previously described (15). After hy-
bridization at 42°C for 18 h, filters were washed in 2x SSC
(1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1%
sodium dodecyl sulfate at room temperature and in 0.2x
SSC-0.1% sodium dodecyl sulfate at 65°C and exposed to
XAR film (Eastman Kodak Co.) at -70°C with intensifying
screens.
RESULTS
Effect of AZT on growth rates and viabilities of T-cell lines.
The growth rates of H9 and Jurkat cells in various concen-
trations of AZT were determined during a period of logarith-
mic growth (Fig. 1). Neither cell line showed a decrease in
growth rate in concentrations of AZT of up to 0.5 ,uM; with
25 puM AZT, the growth rate decreased (Fig. 1). Viability
decreased to 26 and 88% for H9 and Jurkat cells, respec-
tively, at day 3 in 25 pFM AZT. The toxicity of the drug was
more evident in our cultures than in drug-treated, virus-
infected cultures in which cell concentrations were higher.
Suppression of HIV replication in T-cell lines by AZT. Two
T-cell lines susceptible to HIV were used to determine the
effects of AZT on HIV replication. Infected H9 cells became
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FIG. 2. Production of HIV in H9 cells at various concentrations
of AZT. Cells were pretreated with drug or mock treated for 4 h,
infected with the LAV strain of HIV, and washed, and the cultures
were carried in the presence or absence of drug. Samples of
supernatant medium were assayed for RT activity at intervals of a
few days; at each assay time, the cells were adjusted to 2 x 105/ml
and the medium was completely replaced with fresh medium con-
taining drug where indicated. Drug concentrations: no drug (+), 0.5
,uM (O), 5 ,uM (A), 25 ,uM (x), and 100 ,uM (V). Mock infection (-)
is also shown.
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alternate system. Cells were pretreated with AZT for 4 h to
allow loading of intracellular pools with the drug and were
then infected in the presence of drug with a dose of HIV
(LAV strain) predetermined to give high RT levels by 1 week
postinfection (p.i.). Infections and washings were carried out
in the presence of AZT to avoid rapid loss of the drug from
the cells (6). Cells were adjusted to 2 x 1051/ml in fresh
medium containing drug twice weekly at the time of sam-
pling for RT activity. Residual AZT from the drug-treated
cultures was ignored, as it has been shown that AZT does
not interfere with the RT assay in vitro (11). All doses of
AZT were inhibitory, delaying the rise in RT levels as well as
cytopathic effects. With 25 ,uM AZT, virus production was
largely suppressed for 10 days. For both cell lines, however,
in all concentrations of drug except the toxic 100 ,uM level,
virus replication increased to the control infected-culture
level by 20 days or sooner, despite continued presence of
drug (Fig. 2 and 3).
Levels of unintegrated viral DNA in drug-treated cultures.
Samples of Hirt supernatant DNA extracted from the H9
cultures at days 1, 4, and 20 p.i. were subjected to electro-
phoresis through agarose gels, blotted onto nitrocellulose,
and hybridized to a 32P-labeled DNA probe made to the
6.4-kilobase HindIII internal fragment of HIV. At 1 day p.i.,
the level of viral DNA in the control infected culture was
barely detectable (Fig. 4A); in drug-treated samples, viral
DNA was undetectable. At 4 days p.i., the signal from the
control infected culture was at least 10 times stronger than
that from culture with 0.5 ,uM AZT (Fig. 4A), parallel to the
relative amounts of virus produced on that day (Fig. 2). At 20
days p.i., cultures treated with AZT at concentrations of up
to 25 puM contained virus-specific DNA; only about 50% of
the cells were still viable in the culture treated with 100 p.M
AZT at day 20. The reproducibility of RT and DNA levels
was verified in three additional experiments.
Test of virus produced under drug treatment for resistance
to AZT. Since virus was produced at normal levels after a
short interval in drug-treated cultures, we decided to deter-
mine if resistant virus had been generated or if the originally
sensitive virus had broken through the drug treatment. In an
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FIG. 3. Production of HIV in Jurkat cells at various concentra-
tions of AZT. Cells were infected and carried as described in the
legend to Fig. 2. The culture in 100 ,uM AZT was terminated at day
15 when viability had decreased to 16%. Drug concentrations: no
drug (+), 0.5 mM (O), 5 ,uM (A), 25 ,uM (x), and 100 p.M (V). Mock
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FIG. 4. Detection of unintegrated HIV DNA during the course of
HIV infection of H9 cells at various concentrations of AZT.
Cultures were expanded to allow the harvest of approximately 1 x
107 to 2 x 107 cells for Hirt supernatant DNA. DNA (10 [A] or 20 [B]
p.g) was subjected to electrophoresis in agarose gels, blotted onto
nitrocellulose, and probed with 32P-labeled, nick-translated DNA
from the 6.4-kilobase internal Hindlll fragment of LAV. (A) Lanes
1 to 3, Standards corresponding to 100, 10, and 1 copy per cell,
respectively, for 20 p.g of total cellular DNA; lanes 4 to 9, 1 day p.i.;
lanes 10 to 12, 4 days p.i. (B) twenty days p.i. Molecular weight
markers (in kilobase pairs) were A [kbp]) HindIlI fragments run in
the adjacent lane. -V, Control, uninfected cultures; +V-AZT,
control, infected cultures.
virus samples recovered on days 16 and 21 p.i. from cultures
treated with 25 puM AZT were used to inoculate fresh H9
cells, parallel to a parent LAV stock of similar titer (esti-
mated by RT levels), in the presence or absence of 25 p.M
AZT. AZT was present 4 h before infection and throughout
the course of infection. Virus samples from 16 and 21 days
p.i. of the original experiment gave rise to fully productive
infections (RT levels of 500,000 cpm) by day 20, as did the
parent stock. All three samples showed a slow increase in
RT in the absence of drug, reflecting the low initial dose of
virus. The parent LAV stock was diluted such that all three
inocula had approximately the same number of RT counts
per minute. This method was used to normalize the virus
stocks in the absence of a convenient plaque assay. AZT
clearly inhibited the virus recovered at both times of the
original experiment: i.e., both experimental samples be-
haved identically to the parent stock in the presence of drug
(Fig. 5). Thus, there was no evidence that a significant
proportion of the virus produced in the original experiment
had developed resistance to AZT.
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FIG. 5. Test of breakthrough virus for resistance to AZT. Di-
luted parent stock virus (A) and two samples of H9 supernatant
medium from virus breakthrough at 25 p.M AZT, from 16 (B) and 21
(C) days p.i., were tested for resistance to AZT. Each sample was
used to infect H9 cells either in the presence (+) or in the absence
(U) of 25 ,uM AZT. The rise in RT with time was followed by
periodic sampling of the medium. At sampling times, the medium
was completely replaced with fresh medium containing AZT.
DISCUSSION
We have found that HIV infection of two T-cell lines in the
continuing presence of highly inhibitory doses of AZT
proceeded to a highly productive state after an initial period
of inhibition. Others have reported low doses of AZT to be
effective at inhibiting HIV replication. Nakashima et al. (11)
found 0.1 to 1 puM AZT inhibited HIV-induced cytopathic
effect, antigen expression, and PFU production at 3 to 6 days
after HIV infection of human T-cell lymphotropic virus type
I-infected MT4 cells at a multiplicity of infection of 0.002.
Mitsuya et al. (10) found that 5 F.M AZT could reduce
expression of p24 to about 2% of H9 cells as well as protect
TM3 and HTLV-I+ ATH8 cells from HIV-induced killing.
They also reported a fourfold decrease in RT levels at 5 days
p.i. in HIV-infected peripheral blood mononuclear cells in
0.5 p.M AZT. We have used a high multiplicity of infection
(as gauged by RT levels) to observe the effect of the drug on
a single-step growth curve of the virus, classically used to
assay drug effects. In contrast, experiments carried out at a
very low multiplicity of infection (e.g., 0.002) depend on
many rounds of replication to produce detectable virus, with
opportunity for the drug to act at each cycle of replication. In
addition, we have used cells which are not quickly killed by
the virus, thus allowing the infection and reinfection pro-
cesses to proceed. Due to the polyethylene glycol concen-
tration step in our RT assay, we were able to detect
differences of at least 100-fold in RT levels above the
background level (Fig. 2 and 3). These differences in exper-
imental design probably account for the fact that we could
detect virus replication in the presence of drug within 7 to 12
days p.i.
Although AZT may be primarily a competitive inhibitor
for RT, acts as a chain terminator, and perturbs nucleoside
triphosphate pools within the cells (6), our results showed
that complete DNA copies of the viral genome were formed
in the presence of AZT. Since further steps in the virus life
cycle (e.g., production of mRNA and progeny viral RNA)
dependent on cellular RNA polymerase were not affected by
the drug, virus production could then ensue. These proposed
effects of the drug on aspects of the viral replication cycle
are supported by a report that virus production is not
suppressed in cells already producing HIV (11). Virus spread
in the presence of 25 ,uM AZT may have been at low
efficiency. Probably, a majority of the DNA copies initiated
by RT in newly infected cells are prematurely terminated,
but if at least one complete copy is made, a cell may go on to
produce progeny virus. Whether virus spread occurs by
cell-free virus or by cell-to-cell contact, cultures treated with
25 p.M AZT eventually produced as much virus as the
non-drug-treated infected cultures. These results were con-
firmed by the detection of unintegrated viral DNA in drug-
treated H9 cultures when they began producing virus at high
levels. The unintegrated viral DNA in these drug-treated
cultures was present in quantities similar to those in non-
drug-treated infected cultures.
In two samples of HIV recovered after replication in the
presence of a high concentration ofAZT (25 ,uM), we did not
see the generation of resistant mutant virus, although our
preliminary tests were not sensitive enough to detect small
increases in resistance or increases in a very small propor-
tion of the virus population. HIV shows wide variability in
nature, in that every strain isolated appears to have many
differences in sequences over the entire genome. In addition,
changes in sequential isolates from the same patient have
been detected (1-3, 7, 16). Thus, it is conceivable that
naturally occurring nucleotide changes in the pol region
could result in a virus with an altered affinity for AZT
triphosphate or with other changes, causing an AZT-
resistant phenotype. In fact, AZT-resistant RT (in vitro) has
been generated by site-directed mutagenesis of the pol gene
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(9). However, it seems likely that in most cases the drug
lessens the likelihood that RT will be able to generate a
full-length DNA copy of the incoming viral RNA, but the
drug does not completely prevent such generation. Cellular
RNA polymerase II is then able to produce mRNA and
progeny viral RNA. In addition, once the tat gene product
has been produced, it is able to increase the level of
expression of other viral gene products.
In a phase 2 efficacy trial of AZT in patients with late
AIDS-related complex and AIDS, the drug had striking
effects in preventing both opportunistic infections and death
(17, 18). In the phase 1 trials, virus continued to be recov-
ered despite therapy. After 5 mg of drug per kg of body
weight given orally pvery 4 h, the peak level of AZT in the
plasma was reported to be 5 ,M (19), yet virus was isolated
during drug therapy. As there does not exist a good method
to determine virus levels in patient serum, it may be argued
that the virus isolated during AZT treatment is the result of
in vitro release of virus production from in vivo AZT
suppression. However, for at least some patients (6 of 20) in
the AZT-treated group, there was no change in the number
of days required for a positive culture (W. Parks, E. S.
Parks, M. Fischal, R. Makuch, M. Leuther, and J. P. Allain,
Abstr. UCLA Symp. Mol. Cell. Biol. 1987, P021, p. 38). It
may well be that infected cells in patients with AIDS
continue to produce virus at a certain level and that newly
made CD4 cells will become infected at low efficiency even
in the presence of AZT. It appears that our in vitro system
more closely simulates what happens in vivo than do those in
vitro systems that simply show inhibition of HIV replication.
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ADDENDUM
Since submission of our paper, Olsen et al. (J. C. Olsen, P.
Furman, J. A. Fyfe, and R. Swanstrom, J. Virol. 61:2800-2806,
1987) have reported a dose-dependent inhibition by AZT of avian
leukemia virus DNA synthesis in newly infected cells.
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